Compare Archer-Daniels-Midland Co (ADM) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs BioNTech SE - ADR — how do they compare? Archer-Daniels-Midland Co trades at $80.03 (market cap $38.78B), while BioNTech SE - ADR trades at $93.37 (market cap $23.31B). The key difference: Archer-Daniels-Midland Co is the larger of the two by market cap, and Archer-Daniels-Midland Co pays a 2.59% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ADM | BNTX | |
|---|---|---|
Market Cap | $38.78B | $23.31B |
Sector | Consumer Staples | Health |
52-Week High | $87.32 | $119.34 |
52-Week Low | $56.00 | $83.89 |
Enterprise Value | $47.03B | $6.60B |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $79.41, down 1.34% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.84, exceeding expectations, and raised its full-year outlook, driven by biofuels and crushing margins. Valuation ratios like P/E of 21.98 and P/S of 0.48 suggest reasonable pricing relative to peers. Cash flow improved in 2025 with net cash flow of $1.58 billion.
The outlook is positive with analyst consensus price target of $88.00, implying upside. Key opportunities include growth in AgTech and biofuels, while risks involve execution challenges and volatile commodity markets. The stock offers a dividend yield supported by consistent payments, but investors should monitor margin pressures from input costs.
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
